NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal

Lenalidomide in combination with dexamethasone for previously untreated multiple myeloma [ID474]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Company • Celgene (lenalidomide) Patient/carer group • Black Health Agency • Bloodwise • Cancer Black Care • Cancer Equality • Cancer52 • DKMS • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Leukaemia Cancer Society • Leukaemia CARE • Lymphoma Association • Macmillan Cancer Support • Maggie's Centres • Marie Curie • Muslim Council of Britain • Myeloma UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care Professional groups • Association of Cancer Physicians • British Committee for Standards in Haematology (BCSH) • British Geriatrics Society • British Psychosocial Oncology Society • British Society for Haematology • Cancer Research UK • Royal College of General Practitioners	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association for Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator manufacturers • Actavis UK (prednisolone) • Alliance Pharmaceuticals (prednisolone) • Amdipharm (prednisolone) • Aspen Europe (melphalan) • Auden McKenzie (Pharma Division) (dexamethasone) • Baxter Healthcare (cyclophosphamide) • Cardinal Health Martindale Products (dexamethasone) • Celgene (thalidomide) • Concordia International (prednisolone)

Consultees	**Commentators (no right to submit or appeal)**
• Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • UK Clinical Pharmacy Association • UK Health Forum • UK Myeloma Forum • UK Oncology Nursing Society <u>Others</u> • Department of Health • NHS England • NHS Havering CCG • NHS Sandwell and West Birmingham CCG • Welsh Government	• Hospira UK (dexamethasone) • Janssen (bortezomib) • Intrapharm Laboratories (prednisolone) • Rosemont Pharmaceuticals (dexamethasone) • Sandoz Limited (cyclophosphamide) • Wockhardt UK (dexamethasone) • Zentiva (prednisolone) <u>Relevant research groups</u> • Cochrane Haematological Malignancies Group • Institute of Cancer Research • Leuka • Leukaemia Busters • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

<u>Consultees</u>

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non company commentators are invited to nominate clinical or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the company evidence submission to the Institute.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.